Results 251 to 260 of about 208,218 (280)

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin

Bone, 2009
Orchiectomized (ORX) rats were used to examine the extent to which their increased bone resorption and decreased bone density might relate to increases in RANKL, an essential cytokine for bone resorption.
Xiaodong, Li, Michael S, Ominsky, Marina, Stolina, Kelly S, Warmington, Zhaopo, Geng, Qing-Tian, Niu, Frank J, Asuncion, Hong-Lin, Tan, Mario, Grisanti, Denise, Dwyer, Steven, Adamu, Hua Zhu, Ke, W Scott, Simonet, Paul J, Kostenuik   +13 more
openaire   +2 more sources

New actions of rank ligand

Bone, 2012
increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals. Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its ...
openaire   +1 more source

Self-Assembled RANK Induces Osteoclastogenesis Ligand-Independently

Journal of Bone and Mineral Research, 2005
Abstract By immunoprecipitation assay, we showed that mouse RANK was self-assembled through its cytoplasmic domain located at position 534–539, whose domain was different form TRAF binding domains. Moreover, overexpression experiments showed that oligomeric RANK, which was self-associated, induced osteoclastogenesis ligand-independently.
Akira Kudo
exaly   +3 more sources

Osteoprotegerin, rank and rank ligand

2007
The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and ...
Kurban, Sevil, Mehmetoglu, Idris
openaire   +1 more source

Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland

Journal of Cellular Biochemistry, 2002
AbstractReceptor activator of NF‐κB (RANK) ligand (RANKL) and osteoprotegerin (OPG) play essential roles in bone metabolism and immune responses. RANKL activates RANK, which is expressed by osteoclasts and dendritic cells (DC), whereas OPG acts as its decoy receptor. The role of RANKL and OPG in thyroid physiology is unclear. Northern analysis revealed
Lorenz C, Hofbauer, Sibylle, Kluger, Christian A, Kühne, Colin R, Dunstan, Andreas, Burchert, Michael, Schoppet, Andreas, Zielke, Armin E, Heufelder   +7 more
openaire   +2 more sources

RANK ligand is a prerequisite for cancer‐associated osteolytic lesions

The Journal of Pathology, 2002
AbstractBreast cancer is frequently associated with osteolytic bone metastasis, where osteoclasts play a major role in bone destruction. Recently, osteoclast differentiation factor (RANKL) has been identified as a prerequisite for the formation and maintenance of osteoclasts from haematopoietic precursors.
Sohei, Kitazawa, Riko, Kitazawa
openaire   +2 more sources

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

British Journal of Oral and Maxillofacial Surgery, 2010
Since the introduction of bisphosphonates to treat diseases that affect remodelling of bone, increasing numbers of patients with bisphosphonate-related osteonecrosis of the jaws have been reported; the number is currently unknown. Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc ...
K H, Taylor, L S, Middlefell, K D, Mizen
openaire   +2 more sources

TNF‐α expression is transcriptionally regulated by RANK ligand

Journal of Cellular Physiology, 2004
AbstractTumor necrosis factor (TNF)‐α is known for its osteoclastogenic and resorptive activities. Induction of osteoclastogenesis by receptor activator of NF‐κB ligand (RANKL) is accompanied by increased TNF‐α expression. In the present study we investigated the mechanism by which RANKL induces expression of TNF‐α in osteoclast precursors.
W, Zou, A, Amcheslavsky, S, Takeshita, H, Drissi, Z, Bar-Shavit   +4 more
openaire   +2 more sources

Using motion planning to rank ligand binding affinity

Proceedings of the 6th ACM Conference on Bioinformatics, Computational Biology and Health Informatics, 2015
In the drug discovery process, pharmaceutical companies have to screen many drug (or ligand) candidates to find the most promising ones for trial. This process is very costly and attention as turned to computational approaches to predict binding affinity to the desired target protein.
Hsin-Yi Cindy Yeh, Shawna L. Thomas, Nancy M. Amato   +2 more
openaire   +1 more source

Expression of RANK‐ligand in prostate cancer cell lines

Scandinavian Journal of Clinical and Laboratory Investigation, 2009
The molecular mediators of bone remodelling, receptor activator of nuclear factor-kappaB ligand (RANKL), receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerine (OPG), are believed to be involved in the cellular mechanisms by which tumours metastasize to bone. RANKL is a potent stimulator of osteoclastic bone resorption and is expressed
Hendrik, Penno, Olle, Nilsson, Helena, Brändström, Ola, Winqvist, Osten, Ljunggren   +4 more
openaire   +2 more sources